WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000 - 2003
(2000; 81 pages) [French] View the PDF document
Table of Contents
View the documentAcknowledgements
View the documentAbbreviations, Acronyms & WHO Regions
View the documentHighlights - WHO Medicines Strategy: 2000 - 2003
Open this folder and view contents1. The Impact of Essential Drugs
Open this folder and view contents2. Strategic Directions
View the document3. Core Functions Improving Health Through Knowledge, Advocacy and Partnership
Close this folder4. Country Work - Why and How?
View the document4.1 Country work in context
View the document4.2 How WHO works with countries on medicines
View the document4.3 Types of WHO support
Open this folder and view contents5. Framework for Action: Objectives and Expected Outcomes for 2000 - 2003
Open this folder and view contents6. Monitoring Progress
View the documentReferences and Notes
 

4.3 Types of WHO support

Of the specific types of support that WHO provides to countries, three involve projects and activities at country level, while a fourth focuses on intercountry, subregional, regional, and interregional programmes and activities (Figure 7).

Evidently, over time, support to countries may shift. For example, specific technical support to a country (type B) may evolve into a comprehensive programme (type C), or vice-versa. In view of WHO's increasing focus on regional and subregional activities, some pharmaceutical technical support to countries (type B) is being shifted to intercountry programmes (type IC), in the form of regional funds. These are managed jointly by the regional adviser and EDM's regional focal point.

WHO's human and financial resources are limited, however. Criteria for country presence are therefore extensive and cover:

• severity of country need
• country's level of development
• potential for success of proposed activities
• potential for sustainable impact of proposed activities
• demonstration or development value of proposed activities
• opportune timing (for example, resources are available or political commitment is strong)
• cost-effectiveness
• funding opportunities
• support to the pharmaceutical sector provided by other agencies or organizations.


Figure 7: WHO pharmaceutical support to countries and regions is adapted according to national and regional need

 

to previous section to next section
 

Last updated: April 24, 2012